Differential effects of human neuromelanin and synthetic dopamine melanin on neuronal and glial cells

Journal of Neurochemistry

Volumn 95, Issue 2, 2005, Pages 599-608

  Li, Jie ^a   Scheller, Carsten ^a   Koutsilieri, Eleni ^a   Griffiths, Francine ^b   Beart, Philip M ^c   Mercer, Linda D ^c   Halliday, Glenda ^b   Kettle, Emma ^b   Rowe, Dominic ^d   Riederer, Peter ^a   Gerlach, Manfred ^a   Rodriguez, Michael ^e   Double, Kay L ^a,b  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b NEUROSCIENCE RESEARCH AUSTRALIA   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d ROYAL NORTH SHORE HOSPITAL   (Australia)

^e CENTRAL SYDNEY AREA HEALTH SERVICE   (Australia)

Author keywords

Apoptosis; Dopamine; Melanin; Neurodegeneration; Parkinson pathogenesis; Substantia nigra

Indexed keywords

EDETIC ACID; FENTON REAGENT; FERROUS GLUCONATE; HYDROXYL RADICAL; IRON; LACTATE DEHYDROGENASE; NEUROMELANIN; REAGENT; SYNTHETIC DOPAMINE MELANIN; UNCLASSIFIED DRUG;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL LINE; CELL STRAIN; CELL STRAIN SK N SH; CELL STRAIN U373; CONTROLLED STUDY; DOPAMINE UPTAKE; ENZYME ACTIVITY; GLIA CELL; HUMAN; HUMAN CELL; IN VIVO STUDY; LIPID PEROXIDATION; MESENCEPHALON; NERVE CELL; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; SUBSTANTIA NIGRA;

ANIMALS; BRAIN CHEMISTRY; CELL LINE; CELL SURVIVAL; CELLS, CULTURED; DOPAMINE; FLOW CYTOMETRY; HUMANS; HYDROXYL RADICAL; L-LACTATE DEHYDROGENASE; LIPID PEROXIDATION; MELANINS; MICROSCOPY, ELECTRON; NEUROGLIA; NEURONS; OXIDATIVE STRESS; PHAGOCYTOSIS; RATS; TYROSINE 3-MONOOXYGENASE;

EID: 26844473535     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2005.03404.x     Document Type: Article

References (40)

1. Aimi Y. and McGeer P. L. (1996) Lack of toxicity of human neuromelanin to rat brain dopaminergic neurons. Parkinson Rel. Disord. 2, 69-74.
2. Ben-Shachar D., Riederer P. and Youdim M. B. H. (1991) Iron-melanin interaction and lipid peroxidation: implications for Parkinson's disease. J. Neurochem. 57, 1609-1614.
3. Bolzoni F., Giraudo S., Lopiano L., Bergamasco B., Fasano M. and Crippa P. R. (2002). Magnetic investigations of human mesencephalic neuromelanin. Biochem. Biophys. Acta 1586, 210-218.
4. Braak E., Sandmann-Keil D., Rüb U., Gai W. P., de Voa R. A., Jansen Steur E. N. H., Arai K. and Braak H. (2001) a-Synuclein immunopositive Parkinson's disease-related inclusion bodies in lower brain stem nuclei. Acta Neuropathol. 101, 195-201.
5. Cheung N., Hickling Y. and Beart P. (1997) Development and survival of rat embryonic mesencephalic dopaminergic neurones in serum-free, antioxidant-rich primary cultures. Neurosci. Lett. 233, 13-16.
6. D'Agostino A. J. and Luse S. A. (1964) Electron microscopic observations on the human substantia nigra. Neurology 14, 529-536.
7. Double K., Riederer P. and Gerlach M. (1999) The significance of neuromelanin in Parkinson's disease. Drug News Dev. 12, 333-340.
8. Double K., Zecca L., Costo P. et al. (2000) Structural characteristics of human substantia nigra neuromelanin and synthetic dopamine melanins. J. Neurochem. 75, 2583-2589.
9. Double K. L., Gerlach M., Schünemann V., Trautwein A. X., Zecca L., Gallorini M., Youdim M. B. H., Riederer P. and Ben-Shachar D. (2003a) Iron binding characteristics of neuromelanin of the human substantia nigra. Biochem. Pharmacol. 66, 489-494.
10. Double K. L., Halliday G. M., Henderson J., Griffiths F. M., Heinemann T., Riederer P. and Gerlach M. (2003b) The dopamine receptor agonist lisuride attenuates iron-mediated dopaminergic neurodegeneration. Exp. Neurol. 184, 530-535.
11. Duffy P. E. and Tennyson V. M. (1965) Phase and electron microscopic observations of Lewy bodies and melanin granules in the substantia nigra and locus caeruleus in Parkinson's disease. J. Neuropath. Exp. Neur. 24, 398-414.
12. Dzierzega-Lecznar A., Kurkiewicz S., Stepien K., Chodurek E., Wilczok T., Arzberger T., Riederer P. and Gerlach M. (2004) GC/MS analysis of thermally degraded neuromelanin from the human substantia nigra. J. Am. Soc. Mass Spectrom. 15, 920-926.
13. Enochs W. S., Nilges M. J. and Swartz H. M. (1993) Purified human neuromelanin, synthetic dopamine melanin as a potential model pigment, and the normal human substantia nigra: characterization by electron paramagetic resonance spectroscopy. J. Neurochem. 61, 68-79.
14. Faucheux B. A., Martin M. E., Beaumont C., Hauw J. J., Agid Y. and Hirsch E. C. (2003) Neuromelanin associated redox-active iron is increased in the substantia nigra of patients with Parkinson's disease. J. Neurochem. 86, 1142-1148.
15. Fedorow H., Pickford R., Hook J. M., Double K. L., Halliday G. M., Gerlach M., Riederer P. and Gamer B. (2005) Dolichol is the major lipid component of human substantia nigra neuromelanin. J. Neurochem. 92, 990-995.
16. Foley P. and Riederer P. (2000) Influence of neurotoxins and oxidative stress on the onset and progression of Parkinson's disease. J. Neurol. 247, 82-94.
17. Gerlach M., Trautwein A. X., Zecca L., Youdim M. B. H. and Riederer P. (1995) Mössbauer spectroscopy studies of purified human neuromelanin from the substantia nigra. J. Neurochem. 65, 923-926.
18. Good P., Olanow C. and Perl D. (1992) Neuromelanin-containing neurons of the substantia nigra accumulate iron and aluminum in Parkinson's disease: a LAMMA study. Brain Res. 593, 343-346.
19. Hirsch E., Graybiel A. and Agid Y. (1988) Melanized dopamine neurons are differentially susceptible to degeneration in Parkinson's disease. Nature 28, 345-348.
20. Hirsch E. C., Breidert T., Rousselet E., Hunot S., Hartmann A. and Michel P. (2003) The role of glial reaction and inflammation in Parkinson's disease. Ann. NY Acad. Sci. 991, 214-228.
21. Jellinger K., Kienzel E., Rumpelmair G., Riederer P., Stachellberger H., Ben-Shachar D. and Youdim M. B. H. (1992) Iron-melanin complex in substantia nigra of parkinsonian brains: an X-ray micro-analysis. J. Neurochem. 59, 1168-1171.
22. Lopiano L., Chiesa M., Digilio D., Giraudo G., Bergamasco B. and Fasano M. (2000) Q-band EPR investigations of neuromelanin in control and Parkinson's disease patients. Biochem. Biophys. Acta 1500, 306-312.
23. Mercer L. D., Lim M. L. R., Nagley P. and Beart P. M. (2004) Mitochondria, apoptosis and mesencephalic dopmaine neurones. Fed. Eur. Neurosci. Soc. 2, AO53.9.
24. Mercer L. D., Kelly B. L., Home M. K. and Beart P. M. (2005) Dietary polyphenols protect dopamine neurons from oxidative stress and apoptosis: investigations in primary rat mesencephalic cultures. Biochem. Pharmacol. G9, 339-345.
25. Mochizuki H., Nishi K. and Mizuno Y. (1993) Iron-melanin complex is toxic to dopaminergic neurons in nigrostriatal co-culture. Neurodegeneration 2, 1-7.
26. Moses H. L., Ganote C. E., Beaver D. L. and Schuffman S. S. (1966) Light and electron microscopic studies of pigment in human and rhesus monkey substantia nigra and locus coeruleus. Anat. Rec. 155, 167-183.
27. Nguyen A., Gille G., Moldzio R., Hung S.-T. and Rausch W.-D. (2002) Synthetic neuromelanin is toxic to dopaminergic cell cultures. J. Neural Transm. 109, 651-661.
28. Offen D., Ziv I., Barzilai A., Gorodin S., Glater E., Hochman A. and Melamed E. (1997) Dopamine-melanin induces apoptosis in PC12 cells: possible implications for the etiology of Parkinson's disease. Neurochem. Int. 31, 207-216.
29. Offen D., Gorodin S., Melamed E., Hanania J. and Malik Z. (1999) Dopamine-melanin is actively phagocytized by PC12 cells and cerebellar granular cells: possible implications for the etiology of Parkinson's disease. Neurosci. Lett. 260, 101-104.
30. Patthy M., Kiraly I. and Sziraki I. (1995) Separation of dihydroxybenzoates, indicators of in vivo hydroxyl-free radical formation, in the presence of transmitter amines and some metabolites in rodent brain, using high performance liquid chromatography with electrochemical detection. J. Chromatogr. B 664, 247-252.
31. Pilas B., Sarna T., Kalyanaraman B. and Swartz H. (1988) The effect of melanin on iron-associated decomposition of hydrogen peroxide. Free Rad. Biol. Med. 4, 285-293.
32. Sarna T., Menon I. A. and Searly R. C. (1985) Photosensitization of melanins: a comparative study. Photochem. Photobiol. 42, 529-532.
33. Sarna T., Pilas B., Land E. J. and Truscott T. G. (1986) Interaction of radicals from water radiolysis with melanins. Biochim. Biophys. Acta 883, 162-167.
34. Schwyn R. C., King J. S. and Fox C. A. (1970) Pigments in the red nucleus and substantia nigra in man and in representative old and new world monkeys. Bol. Estud. Med. Biol. 26, 139-160.
35. Sofic E., Riederer P., Heinsen H., Beckmann H., Reynolds G. P., Hebenstreit G. and Youdim M. B. (1988) Increased iron (III) and total iron content in post-mortem substantia nigra of parkinsonian brain. J. Neural Transm. 74, 199-205.
36. Sulzer D. and Zecca L. (2000) Intraneuronal dopamine-quinone synthesis: a review. Neurotoxic Res. 1, 181-195.
37. Thome J., Zhang J., Davids E., Foley P., Weijers H., Wiesbeck G., Boning J., Riederer P. and Gerlach M. (1997) Evidence for increased oxidative stress in alcohol-dependent patients provided by quantification of in vivo salicylate hydroxylation products. Alcohol Clin. Exp. Res. 21, 82-85.
38. Wilms H., Rosenstiel P., Sievers J., Deuschl G., Zecca L. and Lucius R. (2003) Activation of microglia by human neuromelanin is NF-κB dependent and involves p38 mitogen-activated protein-kinase: implications for Parkinson's disease. FASEB J. 17, 500-502.
39. Zareba M., Bober A., Korytowski W., Zecca L. and Sama T. (1995) The effect of a synthetic neuromelanin on yield of free hydroxyl radicals generated in model systems. Biochem. Biophys. Acta 1271, 343-348.
40. Zecca L. and Swartz H. M. (1993) Total and paramagnetic metals in human substantia nigra and its neuromelanin. J. Neural Trans. (Park. Dis. Sect.) 5, 203-213.